International Stem Cell Corporation (ISCO) stock price, revenue, and financials

International Stem Cell Corporation market cap is $4.3 m, and annual revenue was $9.47 m in FY 2019

$4.3 M

ISCO Mkt cap, 22-Sept-2020

$1.8 M

International Stem Cell Corporation Revenue Q2, 2020
International Stem Cell Corporation Gross profit (Q2, 2020)1.1 M
International Stem Cell Corporation Gross profit margin (Q2, 2020), %60.3%
International Stem Cell Corporation Net income (Q2, 2020)-1.1 M
International Stem Cell Corporation EBIT (Q2, 2020)-832 K
International Stem Cell Corporation Cash, 30-Jun-20201.3 M
International Stem Cell Corporation EV6.8 M

International Stem Cell Corporation Revenue

International Stem Cell Corporation revenue was $9.47 m in FY, 2019

Embed Graph

International Stem Cell Corporation Revenue Breakdown

Embed Graph

International Stem Cell Corporation revenue breakdown by business segment: 30.3% from Cosmetic and 69.7% from Biomedical

International Stem Cell Corporation revenue breakdown by geographic segment: 85.1% from North America, 9.8% from Asia and 5.1% from Other

International Stem Cell Corporation Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

4.5m4.6m6.1m7.0m7.6b7.2m7.5m11.1m9.5m

Revenue growth, %

14%107510%(100%)4%

Cost of goods sold

1.6m1.3m1.6m1.9m2.1b1.9m2.1m4.1m3.9m

Gross profit

2.9m3.3m4.5m5.1m5.5b5.2m5.3m7.0m5.5m

Gross profit Margin, %

64%72%73%73%73%73%72%63%58%

Sales and marketing expense

1.5m2.1m2.5m2.4m2.6m2.7m

R&D expense

4.4m3.6m3.6m5.4m2.7b2.9m2.7m2.4m1.4m

General and administrative expense

8.4m7.4m6.0m5.6m4.7b4.7m5.2m5.5m7.2m

Operating expense total

14.3m13.1m9.6m11.0m7.4b10.1m10.3m10.5m11.3m

EBIT

(11.4m)(9.8m)(4.9m)(4.9m)(3.5m)(5.7m)

EBIT margin, %

(251%)(215%)(68%)(66%)(31%)(60%)

Interest expense

2.2m20.0k3.0k2.0k11.0m6.0k59.0k1.3m77.0k

Interest income

1.0k44.0k2.0k

Pre tax profit

(9.2m)(9.8m)(10.5m)(12.5m)(2.6b)(1.1m)(6.1m)(2.1m)

Income tax expense

Net Income

(9.2m)(9.8m)(10.5m)(12.5m)(2.6m)(1.1m)(6.1m)(2.1m)(4.3m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.1m842.1k1.1m1.1m1.2m1.3m1.5m1.7m1.6m1.6m2.0m1.6m1.8b2.1b1.6b1.9b1.9b2.0b1.8m1.8b2.6m5.7m3.2m2.2m2.3m2.1m2.4m1.8m

Cost of goods sold

362.1k360.7k324.0k313.0k320.0k334.0k329.0k447.0k439.0k409.0k518.0k418.0k516.0m565.0m377.0m506.0m606.0m553.0m471.0k474.0m825.0k1.9m1.3m841.0k857.0k799.0k857.0k719.0k

Gross profit

752.2k481.3k753.0k743.0k867.0k951.0k1.1m1.2m1.2m1.2m1.4m1.2m1.3b1.6b1.2b1.4b1.3b1.5b1.3m1.4b1.8m3.8m1.9m1.4m1.5m1.3m1.5m1.1m

Gross profit Margin, %

68%57%70%70%73%74%77%73%73%74%74%74%72%74%77%74%69%72%73%74%69%66%59%62%63%62%64%60%

Sales and marketing expense

345.8k364.9k496.0k548.0k477.0k511.0k679.0k632.0k669.0k557.0k708.0k1.3m608.0k692.0k739.0k626.0k517.0k427.0k

R&D expense

1.1m1.1m937.0k865.0k900.0k721.0k974.0k932.0k958.0k1.4m1.4m1.1m567.0m508.0m579.0m852.0m679.0m645.0m739.0k670.0m811.0k1.3m616.0k653.0k268.0k79.0k303.0k200.0k

General and administrative expense

2.1m2.1m2.0m1.8m1.6m1.4m1.7m1.4m1.6m1.3m1.3m1.4m1.1b973.0m1.2b1.2b1.3b1.3b997.0k1.0b1.5m2.7m1.3m1.5m1.4m1.4m1.1m1.3m

Operating expense total

3.6m3.6m3.5m3.2m2.9m2.7m3.3m2.9m3.3m2.7m2.7m2.5m1.6b1.5b1.8b2.0b2.0b1.9b2.3m2.8b3.8m7.2m2.5m2.9m2.4m2.1m2.0m1.9m

Depreciation and amortization

248.0k45.0k

EBIT

(2.9m)(3.1m)(2.7m)(2.4m)(2.1m)(1.7m)(2.2m)(1.7m)(2.1m)(1.0b)(1.0m)(970.0m)(1.2m)(1.6m)(663.0k)(1.5m)(941.0k)(813.0k)(455.0k)(832.0k)

EBIT margin, %

(257%)(371%)(252%)(230%)(175%)(132%)(150%)(102%)(125%)(52%)(57%)(53%)(45%)(27%)(21%)(67%)(41%)(39%)(19%)(46%)

Interest expense

469.1k557.3k42.0k52.0k1.0k12.0k8.0k2.1m1.0k1.0k1.0k2.0m4.0m5.0m1.0m4.0m6.0m1.6m20.0m2.0k9.0k784.0k583.0k293.0k816.0k

Interest income

2.0k

Pre tax profit

(2.4m)(2.6m)(2.7m)(2.5m)(2.1m)(1.7m)(2.2m)(3.8m)(1.4m)(4.4m)(2.0m)(1.3m)723.0m(539.0m)(14.6b)10.9b414.0m(3.1b)568.0k(2.2b)(830.0k)(1.2m)121.0k(906.0k)

Income tax expense

Net Income

(2.4m)(2.6m)(2.7m)(2.5m)(2.1m)(1.7m)(2.2m)(3.8m)(1.4m)(4.4m)(2.0m)(1.3m)723.0m(539.0m)(14.6b)10.9b414.0m(3.1b)568.0k(2.2b)(830.0k)(1.2m)121.0k(906.0k)(648.0k)3.0k(373.0k)(1.1m)

International Stem Cell Corporation Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

1.3m654.0k2.2m1.1m532.0k110.0k304.0k1.1m484.0k

Accounts Receivable

140.0k273.0k306.0k574.0k465.0k651.0k1.5m

Prepaid Expenses

274.0k456.0k418.0k779.0k543.0k207.0k

Inventories

1.3m1.2m658.0k485.0k572.0k1.4m1.3m1.5m1.2m

Current Assets

3.0m2.6m4.6m3.6m3.0m2.5m2.9m3.8m3.5m

PP&E

1.4m1.1m830.0k714.0k375.0k396.0k321.0k469.0k668.0k

Total Assets

5.7m5.4m7.7m7.2m7.1m7.0m6.9m7.8m6.6m

Accounts Payable

885.0k969.0k532.0k670.0k1.1m841.0k830.0k458.0k654.0k

Short-term debt

449.0k2.0m367.0k

Current Liabilities

2.2m7.0m6.9m5.5m3.6m4.8m5.1m1.9m

Long-term debt

718.0k

Total Debt

449.0k2.0m1.1m

Total Liabilities

2.1m5.3m5.2m

Common Stock

80.0k87.0k151.0k239.0k3.0k4.0k6.0k7.0k8.0k

Additional Paid-in Capital

64.0m69.9m77.9m94.8m99.0m101.9m106.6m109.2m103.5m

Retained Earnings

(60.5m)(71.8m)(82.3m)(94.7m)(97.4m)(98.5m)(104.5m)(106.7m)(106.4m)

Total Equity

3.6m(1.8m)(4.2m)321.0k1.6m3.4m2.1m2.5m(2.9m)

Financial Leverage

1.6 x-3.1 x-1.8 x22.4 x4.5 x2 x3.3 x3.1 x-2.3 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

3.6m2.6m6.0m4.3m2.4m1.9m654.0k1.8m991.0k748.0k471.0k611.0k554.0k599.0k1.5m768.0k733.0k676.0k297.0k510.0k447.0k477.0k1.2m615.0k595.0k463.0k708.0k1.3m

Accounts Receivable

341.7k246.3k257.0k210.0k411.0k384.0k454.0k398.0k501.0k605.0k(110.0k)1.5m957.0k976.0k1.1m1.1m694.0k

Prepaid Expenses

290.2k284.0k297.0k291.0k293.0k492.0k663.0k407.0k636.0k504.0k512.0k480.0k440.0k307.0k434.0k379.0k

Inventories

1.3m1.5m1.2m1.3m1.1m1.2m1.4m1.4m1.4m1.5m1.5m1.7m1.8m1.9m1.4m1.4m1.3m1.4m1.4m1.4m1.4m1.7m1.5m1.5m1.3m1.4m1.1m1.0m

Current Assets

5.5m4.6m7.8m6.1m4.2m4.0m3.2m4.0m3.5m3.2m2.9m3.1m3.3m3.6m4.1m3.3m3.1m3.3m2.8m3.1m3.4m4.3m4.7m3.5m3.3m3.3m3.4m3.4m

PP&E

1.5m1.5m1.4m1.2m1.2m1.0m928.0k851.0k742.0k847.0k781.0k630.0k546.0k459.0k379.0k431.0k412.0k355.0k358.0k339.0k336.0k384.0k347.0k652.0k697.0k691.0k630.0k607.0k

Total Assets

8.1m7.3m10.6m8.9m7.1m6.8m6.1m6.9m6.7m6.6m6.4m6.7m6.9m7.2m8.4m7.9m7.5m7.9m7.6m8.0m7.5m8.4m8.7m8.7m8.5m8.3m6.9m6.8m

Accounts Payable

1.0m619.4k719.0k995.0k1.1m430.0k743.0k522.0k518.0k798.0k715.0k1.8m580.0k526.0k602.0k743.0k796.0k725.0k391.0k848.0k1.6m1.8m799.0k806.0k731.0k722.0k534.0k579.0k

Short-term debt

429.0k444.0k464.0k479.0k2.7m2.7m

Current Liabilities

3.3m2.2m2.0m2.2m2.0m1.6m2.6m6.4m6.0m2.0m2.3m6.8m6.1m6.4m21.2m8.8m7.1m7.2m6.0m8.1m5.8m6.8m5.9m4.5m4.5m3.7m4.2m4.1m

Long-term debt

1.0m974.0k929.0k1.1m1.0m

Total Debt

429.0k444.0k464.0k479.0k1.0m974.0k929.0k3.8m3.8m

Total Liabilities

5.5m5.4m4.6m5.4m6.1m

Common Stock

76.6k79.3k87.0k87.0k87.0k112.0k113.0k134.0k157.0k262.0k2.0k2.0k3.0k3.0k4.0k4.0k4.0k4.0k6.0k6.0k7.0k8.0k8.0k8.0k8.0k8.0k

Preferred Stock

2.8k2.8k

Additional Paid-in Capital

59.8m62.8m68.2m68.8m69.3m73.7m74.2m75.0m79.2m87.5m89.1m95.7m96.1m96.7m99.1m100.0m101.0m102.2m102.6m102.9m107.0m107.4m108.4m110.7m102.5m103.0m103.9m104.2m

Retained Earnings

(55.1m)(57.7m)(64.6m)(67.2m)(69.2m)(73.5m)(75.7m)(79.5m)(83.7m)(88.1m)(90.1m)(96.0m)(95.3m)(95.9m)(112.0m)(101.0m)(100.6m)(101.5m)(101.0m)(103.1m)(105.4m)(105.8m)(105.6m)(107.6m)(103.7m)(103.7m)(106.8m)(107.8m)

Total Equity

4.8m5.1m3.7m1.6m211.0k280.0k(1.4m)(4.4m)(4.3m)(365.0k)(846.0k)(79.0k)805.0k834.0k(12.9m)(982.0k)425.0k638.0k1.6m(186.0k)1.6m1.6m2.8m3.2m(1.2m)(676.0k)(2.8m)(3.6m)

Financial Leverage

1.7 x1.4 x2.9 x5.4 x33.7 x24.3 x-4.3 x-1.6 x-1.5 x-18.1 x-7.5 x-84.7 x8.6 x8.7 x-0.7 x-8 x17.7 x12.3 x4.8 x-42.8 x4.6 x5.1 x3.1 x2.7 x-7.2 x-12.2 x-2.4 x-1.9 x

International Stem Cell Corporation Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(9.2m)(9.8m)(10.5m)(12.5m)(2.6m)(1.1m)6.1m(2.1m)(4.3m)

Depreciation and Amortization

494.0k474.0k464.0k458.0k472.0k331.0k326.0k308.0k285.0k

Accounts Receivable

599.0k(133.0k)(55.0k)(147.0k)(86.0k)(27.0k)109.0k(186.0k)(864.0k)

Inventories

(473.0k)109.0k(260.0k)(215.0k)(217.0k)(157.0k)(129.0k)(287.0k)123.0k

Accounts Payable

302.0k192.0k(437.0k)138.0k422.0k(251.0k)(11.0k)(92.0k)196.0k

Cash From Operating Activities

(7.0m)(6.7m)(5.6m)(6.4m)(4.1m)(4.2m)(2.1m)(1.1m)(1.4m)

Purchases of PP&E

(167.0k)(290.0k)(35.0k)(231.0k)(112.0k)(185.0k)(164.0k)

Capital Expenditures

(565.0k)(197.0k)

Cash From Investing Activities

(941.0k)(786.0k)(896.0k)(987.0k)(738.0k)(943.0k)(864.0k)(661.0k)(494.0k)

Dividends Paid

(430.0k)(237.0k)

Cash From Financing Activities

3.5m6.8m8.1m6.3m4.3m4.7m3.2m2.5m1.3m

Net Change in Cash

(4.4m)(683.0k)(422.0k)194.0k771.0k(591.0k)

Interest Paid

3.0k2.0k2.0k14.0k1.0k3.0k5.0k

Free Cash Flow

(7.5m)(6.9m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(4.0m)(6.5m)(2.7m)(5.2m)(7.2m)(1.7m)(3.9m)(7.7m)(1.4m)(4.4m)(2.0m)(1.3m)723.0m(539.0m)(14.6b)10.9b414.0m(3.1b)(2.5m)(4.7m)(830.0k)(1.2m)(1.1m)(906.0k)(1.6m)(1.6m)(373.0k)(1.5m)

Depreciation and Amortization

247.3k384.5k125.0k247.0k369.0k116.0k231.0k347.0k116.0k165.0k248.0k68.0k140.0k215.0k72.0k138.0k203.0k63.0k128.0k

Accounts Receivable

396.8k492.2k(117.0k)(70.0k)(271.0k)(111.0k)(203.0k)(148.0k)(195.0k)(31.0k)(110.0k)(474.0k)(1.1m)(1.1m)(306.0k)(325.0k)(429.0k)377.0k821.0k

Inventories

(471.4k)(625.6k)55.0k29.0k169.0k(11.0k)(179.0k)(201.0k)8.0k(33.0k)(84.0k)(311.0k)51.0k184.0k63.0k77.0k231.0k

Accounts Payable

449.7k36.6k(58.0k)218.0k279.0k(539.0k)(226.0k)(447.0k)(14.0k)798.0k715.0k1.8m580.0k526.0k602.0k743.0k796.0k725.0k(450.0k)7.0k782.0k987.0k249.0k348.0k273.0k264.0k(120.0k)(75.0k)

Cash From Operating Activities

(3.0m)(5.5m)(2.0m)(3.5m)(5.1m)(1.8m)(2.9m)(4.2m)(2.0m)(1.3m)(1.6m)(48.0k)(558.0k)(1.1m)(288.0k)(883.0k)(859.0k)265.0k247.0k

Purchases of PP&E

(60.0k)(89.0k)(57.0k)(149.0k)(157.0k)(58.0k)(113.0k)(146.0k)(3.0k)(22.0k)

Capital Expenditures

(403.6k)(546.8k)(44.0k)(99.0k)(197.0k)(11.0k)(34.0k)(13.0k)

Cash From Investing Activities

(517.7k)(808.5k)(216.0k)(449.0k)(630.0k)(168.0k)(373.0k)(514.0k)(156.0k)(483.0k)(651.0k)(201.0k)(396.0k)(529.0k)(119.0k)(291.0k)(396.0k)(41.0k)(70.0k)

Dividends Paid

(214.4k)(322.8k)(108.0k)(173.0k)(237.0k)

Cash From Financing Activities

1.3m3.1m6.9m6.9m6.8m3.3m3.3m5.9m935.0k2.0m2.7m392.0k1.1m2.5m(53.0k)694.0k643.0k654.0k

Net Change in Cash

(2.2m)(3.2m)4.7m2.9m1.0m1.3m1.1m(1.3m)187.0k400.0k857.0k(460.0k)(480.0k)(612.0k)224.0k831.0k

Interest Paid

1.0k2.0k1.0k2.0k3.0k4.0k2.0k3.0k

Free Cash Flow

(3.4m)(6.1m)(2.1m)(3.6m)(5.3m)(2.9m)(4.3m)(2.0m)

International Stem Cell Corporation Ratios

USDQ2, 2011

Financial Leverage

1.7 x